Jump to content
Powered by


Here you can find dossiers on topics related to the healthcare industry. New articles about state-of-the-art knowledge will always be posted in the overview articles section.

  • Dossier - 29/03/2009

    Biotechnology has since found its way into the food industry and in fact into the entire value creation chain from raw material production to food processing to the sale of the final product. There are many ways in which biotechnology can contribute to better food products. These include the use of enzymes and microorganisms as well as in the production of food supplements and to improve analytic tests.

  • Dossier - 14/01/2009

    The first genetically engineered drug entered the market a little over 25 years ago. Since then more than 100 others have been launched. Many of these biopharmaceuticals have an outstanding effect thus revolutionising the therapeutic options available in many medical sectors. Biopharmaceuticals also have a huge economic potential. The huge potential of these innovative drugs and their importance for Germanys pharmaceutical industry is reflected…

  • Dossier - 20/11/2008

    Is it possible to halt the ageing process? This question was first raised in the 1980s when researchers succeeded in delaying the ageing process in threadworms by modifying a specific gene. Nowadays hundreds of gene mutations are known to prolong the lifespan of yeast fruit flies and mice. Will the human dream of eternal youth eventually become reality? The truth is probably not.

  • Dossier - 29/10/2008

    Signal transduction is one of the most innovative fields of research in the life sciences. Although the scientists are far from being able to understand and decipher everything the signal researchers nevertheless have a good deal of knowledge about the transduction of signals and the different signalling pathways.

  • Dossier - 28/08/2008

    Orphan drugs are drugs for the treatment of rare but severe diseases. Since the number of patients who need such drugs is very small the pharmaceutical industry has naturally been reluctant to develop drugs for the treatment of rare diseases. Therefore the development off orphan drugs is supported by the state including a simplified approval procedure and an exclusive right to sell them for a period of ten years.

  • Dossier - 15/07/2008

    Science needs publicity. Publicly funded research has to account for its projects internally as well as externally. In the past accounting for projects was a matter dealt with in courtly or academic circles today the forum is research journals. This internal communication seldom reaches the public however external communication seeks out the wider lay audience - for many reasons.

  • Dossier - 03/07/2008

    Molecular imaging recognises the functional state of cells and molecules. It visualises biological processes on the cellular and molecular level and is thus able to detect pathological alterations a long time before disease symptoms become apparent. Molecular imaging offers new possibilities for improving diagnosis and enabling more targeted therapies than has previously been possible. Many experts regard molecular imaging as a paradigm shift in…

  • Dossier - 24/04/2008

    The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.

  • Dossier - 25/02/2008

    The conclusion that common features of different species can be traced back to a common ancestor has not been seriously questioned by scientists since the time of Darwin. However 150 years after Darwin ample evidence can be found of the anger bold statements and untruths that religious and pseudoreligious zealots still use to deny this reality.

  • Dossier - 01/02/2008

    Alongside DNA and proteins sugar structures play an important role in cellular transport and communication processes. They are also part of the molecular control and regulation machinery making them of particular interest to biotechnologists. The pharmaceutical industry as well as the food sector and material sciences have realised the potential of sugar structures.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/dossier